Shared on 26 Oct 25

Fair value Increased 3.10%

The average analyst price target for Elanco Animal Health has increased by $0.64 to $21.18, as analysts cite expectations for revenue and EBITDA growth based on recent diligence and market analysis. Analyst Commentary Recent Street research has highlighted a generally optimistic outlook for Elanco Animal Health, though some analysts urge caution regarding future execution and margin expansion.

Shared on 12 Oct 25

Fair value Increased 8.13%

Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings

Analysts have raised their price target for Elanco Animal Health from $18 to $23, citing improved revenue prospects and expectations that profit margins could surpass previous market estimates. Analyst Commentary Bullish Takeaways Bullish analysts see potential for revenue growth to outperform current market expectations, based on recent data analysis and survey feedback.

Shared on 28 Sep 25

Fair value Increased 2.45%

Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings

Elanco Animal Health’s consensus price target was raised to $19.00, reflecting improved revenue outlook, margin upside, and increased analyst confidence in its growth trajectory. Analyst Commentary Bullish analysts cite diligence suggesting revenue upside potential.

Shared on 13 Sep 25

Fair value Increased 2.00%

Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings

Elanco Animal Health’s consensus price target rose marginally to $18.55, as analysts cited improving business stability, innovation-driven sales acceleration, and enhanced confidence in leadership and execution. Analyst Commentary Bullish analysts note stabilization in Elanco’s core business and improved execution, providing a stronger foundation for success.

Shared on 08 Aug 25

Fair value Increased 17%

Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings

Elanco Animal Health’s consensus price target has been raised to $17.45, driven by improved business stability, accelerating growth from an enhanced innovation pipeline, and increased traction of its product CQ. Analyst Commentary Improved core business stability driven by better execution, providing a firmer foundation for future product innovation.

Shared on 29 Jul 25

Fair value Increased 13%

Zenrelia And Credelio Quattro Launches Will Expand Market Presence But FX Headwinds May Impact Earnings

Analysts have raised Elanco Animal Health's price target from $13.80 to $15.55, citing improved core business execution, growing traction of innovation products, and increased confidence in management and the product pipeline. Analyst Commentary Bullish analysts cite stabilization in Elanco's core business due to improved execution, creating a stronger base for future innovation-driven growth.

Shared on 01 May 25